Literature DB >> 1940391

Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen.

J Arvieux1, B Roussel, M C Jacob, M G Colomb.   

Abstract

The requirement of plasma cofactor beta 2-glycoprotein I for binding autoantibodies against anionic phospholipids has been reported. We describe the development of an enzyme-linked immunosorbent assay (ELISA) for anti-phospholipid antibodies using highly purified beta 2-glycoprotein I for coating microtitre plates. Intra- and interassay coefficients of variation, determined with serum pools of low, medium and high positivity, ranged between 3% and 18%. 54 sera from patients with systemic lupus erythematosus and related autoimmune disorders were analyzed by this assay; the results correlated well to those obtained in an ELISA using anionic phospholipids on the solid phase (r = 0.85, P less than 0.001). The two ELISA systems showed similar sensitivities although 8/31 positive sera scored negative in the beta 2-glycoprotein I ELISA. The latter group of eight sera showed significantly higher anti-phosphatidylcholine/anti-phosphatidylserine binding ratios than the group of 23 sera which scored positive in both assays. This new assay should permit accurate measurement of most of the clinically relevant anti-phospholipid antibodies and avoid inconsistencies likely to arise from secondary interactions that characterize lipid-based ELISA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940391     DOI: 10.1016/0022-1759(91)90047-j

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  28 in total

1.  Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot.

Authors:  R R Forastiero; M E Martinuzzo; L O Carreras
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome.

Authors:  Panagiotis Grypiotis; Amelia Ruffatti; Vittorio Pengo; Marta Tonello; Alessandra Biasiolo; Daniela Zamboni; Anna Cavazzana; Silvano Todesco
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

Review 3.  Infections and the antiphospholipid syndrome.

Authors:  Mario García-Carrasco; Claudio Galarza-Maldonado; Claudia Mendoza-Pinto; Ricardo O Escarcega; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI.

Authors:  G M Iverson; E J Victoria; D M Marquis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 5.  Antigenic specificities of "antiphospholipid" autoantibodies.

Authors:  R A Roubey
Journal:  Springer Semin Immunopathol       Date:  1994

Review 6.  Anti-beta 2-glycoprotein I antibodies.

Authors:  J Arvieux; J C Bensa; B Roussel; M G Colomb
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 7.  The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.

Authors:  E N Harris
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

8.  IgG2 subclass restriction of anti-beta 2 glycoprotein 1 antibodies in autoimmune patients.

Authors:  J Arvieux; B Roussel; D Ponard; M G Colomb
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

9.  Measurement of antiphospholipid antibody by ELISA using purified beta 2-glycoprotein I in preeclampsia.

Authors:  T Yamamoto; S Yoshimura; Y Geshi; Y Sasamori; S Okinaga; T Kobayashi; H Mori
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

10.  Anti-phospholipid antibodies in patients with Plasmodium falciparum malaria.

Authors:  P H Jakobsen; S D Morris-Jones; L Hviid; T G Theander; M Høier-Madsen; R A Bayoumi; B M Greenwood
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.